ADGI ADAGIO THERAPEUTICS INC

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference

Fireside Chat Date: Tuesday, November 7, 2023

Fireside Chat Time: 3:50 PM ET

Location: New York, NY

Evercore ISI 6th Annual HealthCONx Conference

Fireside Chat Date: Thursday, November 30, 2023

Fireside Chat Time: 10:50 AM ET

Location: Miami, FL

Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit  to learn more.



Contacts:

Scott Young

(781) 208-1747

Gabriella Linville-Engler

(781) 208-0160



EN
31/10/2023

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pi...

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated mid-2026DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate prevention of COVID, at three months, from a single intramuscular (IM) dose of VYD2311, with longer-term protection ant...

October 6, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. “We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications ...

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health comm...

September 17, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

SPEAR Study Group to Present its Recommended Long COVID Antibody Study...

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to evaluate the ability of VYD2311 to decrease circulating spike protein in eligible patients and to explore potential associated clinical benefits Study design contemplates maintaining high antivir...

September 4, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences: Cantor Global Healthcare Conference 2025Fireside Chat Date: Wednesday, September 3, 2025Fireside Chat Time: 2:10 PM ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment ConferenceFireside Chat Date: Monday, September 8, 2025Fireside Chat Time: 12:00 PM ETLocation: New York, NY Live webcasts of the fireside chats will be available in the investor section o...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch